Industry Research Reports
Home > Reports > Service & Software > Global Tissue-Based Diagnostics Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Tissue-Based Diagnostics Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Service & Software
Published Date: 2025-10-25
Pages: 129 Pages
Report ld: 5251681
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Tissue-Based Diagnostics Market Size(US$)
CAGR 2025-2031
6.7%
Market Size,2031
USD 9,055
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 6,136 million
Market Forecast in 2031(Value)
US$ 9,055 million
CAGR
6.7%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Tissue-Based Diagnostics market is projected to grow from US$ 5787 million in 2024 to US$ 9055 million by 2031, at a CAGR of 6.7% (2025-2031), driven by critical product segments and diverse end‑use applications.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Tissue-Based Diagnostics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Roche
- Danaher
- Thermo Fisher Scientific
- Abbott
- Agilent Technologies
- ABCAM
- Merck
- BD
- Hologic
- Bio Rad
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)
- Digital Pathology and Workflow Management
- Special Staining
Segment by Application
- Hospitals
- Research Laboratories
- Pharmaceutical Companies
- Contract Research Organizations
- Other
CHAPTER OUTLINE
Chapter 1: Defines the Tissue-Based Diagnostics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; top-tier players 2024 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Tissue-Based Diagnostics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Tissue-Based Diagnostics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Immunohistochemistry (IHC)
1.2.3 In Situ Hybridization (ISH)
1.2.4 Digital Pathology and Workflow Management
1.2.5 Special Staining
1.3 Market Segmentation by Application
1.3.1 Global Tissue-Based Diagnostics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Research Laboratories
1.3.4 Pharmaceutical Companies
1.3.5 Contract Research Organizations
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Tissue-Based Diagnostics Revenue Estimates and Forecasts 2020-2031
2.2 Global Tissue-Based Diagnostics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Tissue-Based Diagnostics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Tissue-Based Diagnostics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Immunohistochemistry (IHC) Market Size by Players
3.3.2 In Situ Hybridization (ISH) Market Size by Players
3.3.3 Digital Pathology and Workflow Management Market Size by Players
3.3.4 Special Staining Market Size by Players
3.4 Global Tissue-Based Diagnostics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Tissue-Based Diagnostics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Tissue-Based Diagnostics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Tissue-Based Diagnostics Market Size by Type (2020-2031)
6.4 North America Tissue-Based Diagnostics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Tissue-Based Diagnostics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Tissue-Based Diagnostics Market Size by Type (2020-2031)
7.4 Europe Tissue-Based Diagnostics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Tissue-Based Diagnostics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Tissue-Based Diagnostics Market Size by Type (2020-2031)
8.4 Asia-Pacific Tissue-Based Diagnostics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Tissue-Based Diagnostics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Tissue-Based Diagnostics Market Size by Type (2020-2031)
9.4 Central and South America Tissue-Based Diagnostics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Tissue-Based Diagnostics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Tissue-Based Diagnostics Market Size by Type (2020-2031)
10.4 Middle East and Africa Tissue-Based Diagnostics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Tissue-Based Diagnostics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Business Overview
11.1.3 Roche Tissue-Based Diagnostics Product Features and Attributes
11.1.4 Roche Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.1.5 Roche Tissue-Based Diagnostics Revenue by Product in 2024
11.1.6 Roche Tissue-Based Diagnostics Revenue by Application in 2024
11.1.7 Roche Tissue-Based Diagnostics Revenue by Geographic Area in 2024
11.1.8 Roche Tissue-Based Diagnostics SWOT Analysis
11.1.9 Roche Recent Developments
11.2 Danaher
11.2.1 Danaher Corporation Information
11.2.2 Danaher Business Overview
11.2.3 Danaher Tissue-Based Diagnostics Product Features and Attributes
11.2.4 Danaher Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.2.5 Danaher Tissue-Based Diagnostics Revenue by Product in 2024
11.2.6 Danaher Tissue-Based Diagnostics Revenue by Application in 2024
11.2.7 Danaher Tissue-Based Diagnostics Revenue by Geographic Area in 2024
11.2.8 Danaher Tissue-Based Diagnostics SWOT Analysis
11.2.9 Danaher Recent Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Corporation Information
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Tissue-Based Diagnostics Product Features and Attributes
11.3.4 Thermo Fisher Scientific Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.3.5 Thermo Fisher Scientific Tissue-Based Diagnostics Revenue by Product in 2024
11.3.6 Thermo Fisher Scientific Tissue-Based Diagnostics Revenue by Application in 2024
11.3.7 Thermo Fisher Scientific Tissue-Based Diagnostics Revenue by Geographic Area in 2024
11.3.8 Thermo Fisher Scientific Tissue-Based Diagnostics SWOT Analysis
11.3.9 Thermo Fisher Scientific Recent Developments
11.4 Abbott
11.4.1 Abbott Corporation Information
11.4.2 Abbott Business Overview
11.4.3 Abbott Tissue-Based Diagnostics Product Features and Attributes
11.4.4 Abbott Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.4.5 Abbott Tissue-Based Diagnostics Revenue by Product in 2024
11.4.6 Abbott Tissue-Based Diagnostics Revenue by Application in 2024
11.4.7 Abbott Tissue-Based Diagnostics Revenue by Geographic Area in 2024
11.4.8 Abbott Tissue-Based Diagnostics SWOT Analysis
11.4.9 Abbott Recent Developments
11.5 Agilent Technologies
11.5.1 Agilent Technologies Corporation Information
11.5.2 Agilent Technologies Business Overview
11.5.3 Agilent Technologies Tissue-Based Diagnostics Product Features and Attributes
11.5.4 Agilent Technologies Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.5.5 Agilent Technologies Tissue-Based Diagnostics Revenue by Product in 2024
11.5.6 Agilent Technologies Tissue-Based Diagnostics Revenue by Application in 2024
11.5.7 Agilent Technologies Tissue-Based Diagnostics Revenue by Geographic Area in 2024
11.5.8 Agilent Technologies Tissue-Based Diagnostics SWOT Analysis
11.5.9 Agilent Technologies Recent Developments
11.6 ABCAM
11.6.1 ABCAM Corporation Information
11.6.2 ABCAM Business Overview
11.6.3 ABCAM Tissue-Based Diagnostics Product Features and Attributes
11.6.4 ABCAM Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.6.5 ABCAM Recent Developments
11.7 Merck
11.7.1 Merck Corporation Information
11.7.2 Merck Business Overview
11.7.3 Merck Tissue-Based Diagnostics Product Features and Attributes
11.7.4 Merck Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.7.5 Merck Recent Developments
11.8 BD
11.8.1 BD Corporation Information
11.8.2 BD Business Overview
11.8.3 BD Tissue-Based Diagnostics Product Features and Attributes
11.8.4 BD Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.8.5 BD Recent Developments
11.9 Hologic
11.9.1 Hologic Corporation Information
11.9.2 Hologic Business Overview
11.9.3 Hologic Tissue-Based Diagnostics Product Features and Attributes
11.9.4 Hologic Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.9.5 Hologic Recent Developments
11.10 Bio Rad
11.10.1 Bio Rad Corporation Information
11.10.2 Bio Rad Business Overview
11.10.3 Bio Rad Tissue-Based Diagnostics Product Features and Attributes
11.10.4 Bio Rad Tissue-Based Diagnostics Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Tissue-Based DiagnosticsIndustry Chain Analysis
12.1 Tissue-Based Diagnostics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Tissue-Based Diagnostics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Tissue-Based Diagnostics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Tissue-Based Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Tissue-Based Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Tissue-Based Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Tissue-Based Diagnostics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Tissue-Based Diagnostics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Tissue-Based Diagnostics Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Tissue-Based Diagnostics Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Tissue-Based Diagnostics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tissue-Based Diagnostics as of 2024)
Table 11. Global Tissue-Based Diagnostics Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Tissue-Based Diagnostics Companies Headquarters
Table 13. Global Tissue-Based Diagnostics Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Tissue-Based Diagnostics Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Tissue-Based Diagnostics Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Tissue-Based Diagnostics Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Tissue-Based Diagnostics Revenue by Application (2026-2031) & (US$ Million)
Table 21. Tissue-Based Diagnostics High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Tissue-Based Diagnostics Growth Accelerators and Market Barriers
Table 25. North America Tissue-Based Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Tissue-Based Diagnostics Growth Accelerators and Market Barriers
Table 27. Europe Tissue-Based Diagnostics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Tissue-Based Diagnostics Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Tissue-Based Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Tissue-Based Diagnostics Investment Opportunities and Key Challenges
Table 31. Central and South America Tissue-Based Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Tissue-Based Diagnostics Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Tissue-Based Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Roche Corporation Information
Table 35. Roche Description and Major Businesses
Table 36. Roche Product Features and Attributes
Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Roche Revenue Proportion by Product in 2024
Table 39. Roche Revenue Proportion by Application in 2024
Table 40. Roche Revenue Proportion by Geographic Area in 2024
Table 41. Roche Tissue-Based Diagnostics SWOT Analysis
Table 42. Roche Recent Developments
Table 43. Danaher Corporation Information
Table 44. Danaher Description and Major Businesses
Table 45. Danaher Product Features and Attributes
Table 46. Danaher Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Danaher Revenue Proportion by Product in 2024
Table 48. Danaher Revenue Proportion by Application in 2024
Table 49. Danaher Revenue Proportion by Geographic Area in 2024
Table 50. Danaher Tissue-Based Diagnostics SWOT Analysis
Table 51. Danaher Recent Developments
Table 52. Thermo Fisher Scientific Corporation Information
Table 53. Thermo Fisher Scientific Description and Major Businesses
Table 54. Thermo Fisher Scientific Product Features and Attributes
Table 55. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 57. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 58. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 59. Thermo Fisher Scientific Tissue-Based Diagnostics SWOT Analysis
Table 60. Thermo Fisher Scientific Recent Developments
Table 61. Abbott Corporation Information
Table 62. Abbott Description and Major Businesses
Table 63. Abbott Product Features and Attributes
Table 64. Abbott Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Abbott Revenue Proportion by Product in 2024
Table 66. Abbott Revenue Proportion by Application in 2024
Table 67. Abbott Revenue Proportion by Geographic Area in 2024
Table 68. Abbott Tissue-Based Diagnostics SWOT Analysis
Table 69. Abbott Recent Developments
Table 70. Agilent Technologies Corporation Information
Table 71. Agilent Technologies Description and Major Businesses
Table 72. Agilent Technologies Product Features and Attributes
Table 73. Agilent Technologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Agilent Technologies Revenue Proportion by Product in 2024
Table 75. Agilent Technologies Revenue Proportion by Application in 2024
Table 76. Agilent Technologies Revenue Proportion by Geographic Area in 2024
Table 77. Agilent Technologies Tissue-Based Diagnostics SWOT Analysis
Table 78. Agilent Technologies Recent Developments
Table 79. ABCAM Corporation Information
Table 80. ABCAM Description and Major Businesses
Table 81. ABCAM Product Features and Attributes
Table 82. ABCAM Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. ABCAM Recent Developments
Table 84. Merck Corporation Information
Table 85. Merck Description and Major Businesses
Table 86. Merck Product Features and Attributes
Table 87. Merck Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Merck Recent Developments
Table 89. BD Corporation Information
Table 90. BD Description and Major Businesses
Table 91. BD Product Features and Attributes
Table 92. BD Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. BD Recent Developments
Table 94. Hologic Corporation Information
Table 95. Hologic Description and Major Businesses
Table 96. Hologic Product Features and Attributes
Table 97. Hologic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Hologic Recent Developments
Table 99. Bio Rad Corporation Information
Table 100. Bio Rad Description and Major Businesses
Table 101. Bio Rad Product Features and Attributes
Table 102. Bio Rad Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Bio Rad Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Tissue-Based Diagnostics Product Picture
Figure 2. Global Tissue-Based Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Immunohistochemistry (IHC) Product Picture
Figure 4. In Situ Hybridization (ISH) Product Picture
Figure 5. Digital Pathology and Workflow Management Product Picture
Figure 6. Special Staining Product Picture
Figure 7. Global Tissue-Based Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospitals
Figure 9. Research Laboratories
Figure 10. Pharmaceutical Companies
Figure 11. Contract Research Organizations
Figure 12. Other
Figure 13. Tissue-Based Diagnostics Report Years Considered
Figure 14. Global Tissue-Based Diagnostics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 16. Global Tissue-Based Diagnostics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Tissue-Based Diagnostics Revenue Market Share by Region (2020-2031)
Figure 18. Global Tissue-Based Diagnostics Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Immunohistochemistry (IHC) Revenue Market Share by Player in 2024
Figure 21. In Situ Hybridization (ISH) Revenue Market Share by Player in 2024
Figure 22. Digital Pathology and Workflow Management Revenue Market Share by Player in 2024
Figure 23. Special Staining Revenue Market Share by Player in 2024
Figure 24. Global Tissue-Based Diagnostics Revenue Market Share by Type (2020-2031)
Figure 25. Global Tissue-Based Diagnostics Revenue Market Share by Application (2020-2031)
Figure 26. North America Tissue-Based Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Players Tissue-Based Diagnostics Revenue (US$ Million) in 2024
Figure 28. North America Tissue-Based Diagnostics Revenue (US$ Million) by Type (2020 - 2031)
Figure 29. North America Tissue-Based Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 30. US Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 31. Canada Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 32. Mexico Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 33. Europe Tissue-Based Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 34. Europe Top 5 Players Tissue-Based Diagnostics Revenue (US$ Million) in 2024
Figure 35. Europe Tissue-Based Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 36. Europe Tissue-Based Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 37. Germany Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 38. France Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 39. U.K. Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 40. Italy Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 41. Russia Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Tissue-Based Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Top 8 Players Tissue-Based Diagnostics Revenue (US$ Million) in 2024
Figure 44. Asia-Pacific Tissue-Based Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 45. Asia-Pacific Tissue-Based Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 46. Indonesia Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 47. Japan Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 48. South Korea Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 49. Australia Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 50. India Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 51. Indonesia Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 52. Vietnam Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 53. Malaysia Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 54. Philippines Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 55. Singapore Tissue-Based Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 56. Central and South America Tissue-Based Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Central and South America Top 5 Players Tissue-Based Diagnostics Revenue (US$ Million) in 2024
Figure 58. Central and South America Tissue-Based Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 59. Central and South America Tissue-Based Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 60. Brazil Tissue-Based Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 61. Argentina Tissue-Based Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 62. Middle East and Africa Tissue-Based Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Middle East and Africa Top 5 Players Tissue-Based Diagnostics Revenue (US$ Million) in 2024
Figure 64. South America Tissue-Based Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 65. Middle East and Africa Tissue-Based Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 66. GCC Countries Tissue-Based Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 67. Israel Tissue-Based Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 68. Egypt Tissue-Based Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 69. South Africa Tissue-Based Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 70. Tissue-Based Diagnostics Industry Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Tissue-Based Diagnostics in 2031?
The global market size of Tissue-Based Diagnostics in 2031 was 9055 Million USD.
Which companies rank high in the global Tissue-Based Diagnostics market?
What was the global market size of Tissue-Based Diagnostics in 2025?
Which region is expected to have the highest market share?
What is the annual compound growth rate of the global Tissue-Based Diagnostics market size from 2025 to 2031?
Related Reports
Tissue-Based Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Tissue-Based Diagnostics was estimated to be worth US$ 6136 million in 2025 and is projected to reach US$ 9601 million, growing at a CAGR of 6.7% from 2026 to 2032.
Published Date: 2026-07-09
Pages: 105
USD 3950.00
(Single User License)
Global Tissue-Based Diagnostics Market Research Report 2026
The global Tissue-Based Diagnostics market was valued at US$ 6136 million in 2025 and is anticipated to reach US$ 9601 million by 2032, at a CAGR of 6.7% from 2026 to 2032.
Published Date: 2026-04-21
Pages: 110
USD 2900.00
(Single User License)
Global Tissue-Based Diagnostics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Tissue-Based Diagnostics market size was US$ 5787 million in 2024 and is forecast to a readjusted size of US$ 9055 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 78
USD 4250.00
(Single User License)
Tissue-Based Diagnostics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Tissue-Based Diagnostics was estimated to be worth US$ 5787 million in 2024 and is forecast to a readjusted size of US$ 9055 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 99
USD 3950.00
(Single User License)
Global Tissue-Based Diagnostics Market Research Report 2025
The global market for Tissue-Based Diagnostics was valued at US$ 5787 million in the year 2024 and is projected to reach a revised size of US$ 9055 million by 2031, growing at a CAGR of 6.7% during the forecast period.
Published Date: 2025-02-21
Pages: 72
USD 2900.00
(Single User License)
Global Tissue-Based Diagnostics Market Insights, Forecast to 2030
Market Analysis and Insights: Global Tissue-Based Diagnostics Market
Published Date: 2024-04-08
Pages: 110
USD 4900.00
(Single User License)
Tissue-Based Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Tissue-Based Diagnostics was estimated to be worth US$ 5321 million in 2023 and is forecast to a readjusted size of US$ 8054.2 million by 2030 with a CAGR of 6.7% during the forecast period 2024-2030
Published Date: 2024-02-22
Pages: 110
USD 3950.00
(Single User License)
Global Tissue-Based Diagnostics Market Research Report 2024
The global Tissue-Based Diagnostics market was valued at US$ 5321 million in 2023 and is anticipated to reach US$ 8054.2 million by 2030, witnessing a CAGR of 6.7% during the forecast period 2024-2030.
Published Date: 2024-02-06
Pages: 81
USD 2900.00
(Single User License)
Tissue-Based Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Tissue-Based Diagnostics was estimated to be worth US$ 6136 million in 2025 and is projected to reach US$ 9601 million, growing at a CAGR of 6.7% from 2026 to 2032.
Published: 2026-07-09
Pages: 105
USD 3950.00 (Single User License)Global Tissue-Based Diagnostics Market Research Report 2026
The global Tissue-Based Diagnostics market was valued at US$ 6136 million in 2025 and is anticipated to reach US$ 9601 million by 2032, at a CAGR of 6.7% from 2026 to 2032.
Published: 2026-04-21
Pages: 110
USD 2900.00 (Single User License)Global Tissue-Based Diagnostics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Tissue-Based Diagnostics market size was US$ 5787 million in 2024 and is forecast to a readjusted size of US$ 9055 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 78
USD 4250.00 (Single User License)Tissue-Based Diagnostics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Tissue-Based Diagnostics was estimated to be worth US$ 5787 million in 2024 and is forecast to a readjusted size of US$ 9055 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 99
USD 3950.00 (Single User License)Global Tissue-Based Diagnostics Market Research Report 2025
The global market for Tissue-Based Diagnostics was valued at US$ 5787 million in the year 2024 and is projected to reach a revised size of US$ 9055 million by 2031, growing at a CAGR of 6.7% during the forecast period.
Published: 2025-02-21
Pages: 72
USD 2900.00 (Single User License)Global Tissue-Based Diagnostics Market Insights, Forecast to 2030
Market Analysis and Insights: Global Tissue-Based Diagnostics Market
Published: 2024-04-08
Pages: 110
USD 4900.00 (Single User License)Tissue-Based Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Tissue-Based Diagnostics was estimated to be worth US$ 5321 million in 2023 and is forecast to a readjusted size of US$ 8054.2 million by 2030 with a CAGR of 6.7% during the forecast period 2024-2030
Published: 2024-02-22
Pages: 110
USD 3950.00 (Single User License)Global Tissue-Based Diagnostics Market Research Report 2024
The global Tissue-Based Diagnostics market was valued at US$ 5321 million in 2023 and is anticipated to reach US$ 8054.2 million by 2030, witnessing a CAGR of 6.7% during the forecast period 2024-2030.
Published: 2024-02-06
Pages: 81
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now